Shares of Rokit Healthcare, an AI-based organ regeneration platform company, are showing strong performance. The stock is believed to be reacting to the news that the company has completed the registration of a core technology patent related to cartilage regeneration with the United States Patent and Trademark Office (USPTO).
As of 9:12 a.m. on June 18, Rokit Healthcare was trading at 16,080 won, up 16.78% from the previous day.
The U.S. patent covers "ultra-personalized hyaline cartilage regeneration therapeutic compositions," signifying that Rokit Healthcare has secured technological independence and global competitiveness for its AI-based cartilage regeneration platform.
A company representative stated, "This is a structurally and fundamentally differentiated cartilage regeneration treatment technology, completely distinct from existing temporary pain relief therapies." The representative added, "We expect rapid commercialization through our AI hyaline cartilage regeneration platform, which integrates AI analysis, cartilage regeneration bio-ink technology, and bioprinting."
According to Credence Research, a U.S.-based market research firm, the U.S. cartilage regeneration market was valued at approximately $2.33 billion in 2024 and is projected to surpass $3.6 billion by 2032, with a compound annual growth rate (CAGR) of 5.7%. The U.S. cartilage regeneration market is rapidly expanding into a high-value-added treatment market due to factors such as an increasingly aging population, a rise in sports-related injuries, and an increase in early diagnosis of knee osteoarthritis.
The company representative said, "This patent registration fulfills all scientific, business, and legal requirements necessary for the practical deployment of cartilage regeneration therapies in the U.S. and other advanced markets." The representative continued, "We are initiating a full-scale commercialization strategy in the U.S. market, including negotiations with global distribution partners, entry into hospital networks, and expansion of strategic alliances."
In fact, Rokit Healthcare has already demonstrated the global business potential of its cartilage regeneration products by entering the South American market. With the registration of the U.S. patent as a turning point, the company is expected to accelerate its entry into the world's largest cartilage regeneration market.
Chief Executive Officer Yoo Seokhwan emphasized, "The patent registration is evidence that Rokit Healthcare's AI ultra-personalized cartilage regeneration technology has been recognized for its structural stability and differentiation in the global market," and added, "As a first mover in the global cartilage regeneration market, we will achieve tangible results in the U.S. as well."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
